Neuroarchitectural Recovery Model of Post-stroke Patients
Launched by CHINESE UNIVERSITY OF HONG KONG · Feb 10, 2025
Trial Information
Current as of August 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
A.1. Introduction Between 1990 and 2016, the mean lifetime risk of stroke increased from 23% to 25%.1 Stroke was one disease that resulted in long-term neurological deficits and disabilities1,2, which burden both the family and society. Post-stroke rehabilitation has been designed to promote the regain of daily functions.3 A previous study revealed that the heterogeneity of the neurotrauma due to a stroke, as well as the constraints of neuroplastic responses to clinical interventions, influenced the patient's rehabilitation outcomes.4 For example, substantial variability existed in the gain...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Chronic post-stroke patients between 50 and 80 years old, and with the first-time ischemic stroke occurring three months or more after onset will be recruited to participate in the study. The reason for choosing chronic post-stroke patients is to minimize the effect of spontaneous recovery,55 which may confound the treatment-induced recovery. The recruited patients should present with motor deficits in the upper and/or lower extremities due to the stroke as measured using the Fugl-Meyer Motor Scale
- Exclusion Criteria:
- • Patients with voluntary extension ≤ 10° in the metacarpophalangeal or interphalangeal joints, or ≤ 20° in the wrist; severe balance or walking disorders as indicated by the need for assistance in any activities of daily living; significant cognitive decline (score \<16) measured with the The Hong Kong version of Montreal Cognitive Assessment (HK-MoCA);56 or a history of prior stroke, brain neoplasm, intracranial hemorrhages, transient ischemic attacks, diffusion abnormalities due to nonvascular etiology (for example, posterior reversible encephalopathy syndrome or global hypoxic ischemic encephalopathy), or other neurological/psychiatric or medical conditions that preclude active participation in research and/or may alter the interpretation of the behavioral/imaging studies (e.g., dementia, schizophrenia)
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hung Hom, , Hong Kong
Patients applied
Trial Officials
Sai Kam Hui, Ph.D.
Study Chair
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported